New Brunswick, NJ — Tumors require fuel for growth and must obtain this nutrition from the body of the patient in which they reside. Most of the nutrients that support tumor growth come from circulating blood.
Cancer cells need this fuel, which can come in the form of proteins, amino acids, lipids, sugars and other metabolites, to synthesize the building blocks for new cancer cells and to maintain normal cellular functions.
The demand for fuel is most likely higher in cancer cells than most normal tissues, which has led researchers to the following questions:
What specific fuels are important for cancer cells? Where do they come from? What are they used for? Can the dependency of tumors on nutrients supplied from the host be therapeutically exploited?
Cancer cells need this fuel, which can come in the form of proteins, amino acids, lipids, sugars and other metabolites, to synthesize the building blocks for new cancer cells and to maintain normal cellular functions.
The demand for fuel is most likely higher in cancer cells than most normal tissues, which has led researchers to the following questions:
What specific fuels are important for cancer cells? Where do they come from? What are they used for? Can the dependency of tumors on nutrients supplied from the host be therapeutically exploited?
The laboratories of Eileen White, PhD, deputy director, chief scientific officer, and associate director for basic science at Rutgers Cancer Institute of New Jersey; and Joshua D. Rabinowitz, MD, PhD, professor in the Department of Chemistry and Lewis-Sigler Institute for Integrative Genomics at Princeton University and a research member at Rutgers Cancer Institute aim to answer these questions with the support of a $2.24 million competing renewal of grant (R01CA163591) awarded from the National Cancer Institute (NCI).
The research will focus on melanoma and lung cancer caused by mutations in genes known as K-ras and Braf.
Using the analytical method of mass spectroscopy to measure molecular compounds by mass, investigators aim to identify the circulating nutrients that are consumed by tumors and determine why they are important for their growth and survival.
The therapeutic utility of cutting off the supply and use of specific nutrients to tumors will be tested by eliminating them from the diet or by blocking their production or availability.
“This is an exciting new area of research with great potential to develop new therapeutic approaches to fight cancer,” notes Dr. White, who is also a distinguished professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University.
The award period begins July 1 and runs through June 2022. The work will build on research supported over the previous five years by a $2.3 million NCI grant (R01CA163591).
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, Rutgers Cancer Institute is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention both at its flagship New Brunswick location and at its Newark campus at Rutgers Cancer Institute of New Jersey at University Hospital.
Physician-scientists across Rutgers Cancer Institute also engage in translational research, transforming their laboratory discoveries into clinical practice that supports patients on both campuses.
To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
The research will focus on melanoma and lung cancer caused by mutations in genes known as K-ras and Braf.
Using the analytical method of mass spectroscopy to measure molecular compounds by mass, investigators aim to identify the circulating nutrients that are consumed by tumors and determine why they are important for their growth and survival.
The therapeutic utility of cutting off the supply and use of specific nutrients to tumors will be tested by eliminating them from the diet or by blocking their production or availability.
“This is an exciting new area of research with great potential to develop new therapeutic approaches to fight cancer,” notes Dr. White, who is also a distinguished professor of molecular biology and biochemistry in the School of Arts and Sciences at Rutgers University.
The award period begins July 1 and runs through June 2022. The work will build on research supported over the previous five years by a $2.3 million NCI grant (R01CA163591).
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, Rutgers Cancer Institute is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention both at its flagship New Brunswick location and at its Newark campus at Rutgers Cancer Institute of New Jersey at University Hospital.
Physician-scientists across Rutgers Cancer Institute also engage in translational research, transforming their laboratory discoveries into clinical practice that supports patients on both campuses.
To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving.
